OmniAb Business Summary

OmniAb, Inc. (OABI) operates a high-throughput therapeutic antibody discovery platform powered by its proprietary "Biological Intelligence" technology. The company generates revenue through a multi-tiered licensing model that includes upfront access fees, technology investment fees, and service-based payments, supplemented by long-term value drivers such as clinical and regulatory milestone payments and tiered royalties on net sales of partner-developed drugs. Its primary business segment centers on a diverse suite of transgenic animal platforms—including OmniRat, OmniMouse, OmniChicken, and the recently launched OmniUltra for cow-like antibodies—integrated with the OmniDeep AI-driven computational suite and xPloration high-throughput screening. OmniAb competes directly with AbCellera Biologics, the privately held Adimab, and internal discovery divisions of major pharmaceutical firms, positioning itself as a specialized technology provider that offers the industry’s most diverse range of transgenic host systems for discovering fully human antibodies. Following its 2022 spinoff from Ligand Pharmaceuticals, OmniAb is led by President and CEO Matthew W. Foehr, who previously served as President and COO of Ligand and held senior R&D roles at GlaxoSmithKline and Stiefel Laboratories. The executive team includes EVP and CFO Kurt Gustafson, a veteran of Amgen and Halozyme Therapeutics, and Chief Legal Officer Charles Berkman, formerly General Counsel at Ligand. Technical leadership is bolstered by Bill Harriman (SVP of Antibody Discovery) and Bob Chen (VP of Discovery Systems), both of whom joined via the strategic acquisitions of Crystal Bioscience and xCella Biosciences, respectively. The company’s board is chaired by former Ligand CEO John Higgins and features distinguished members such as Nobel Laureate Dr. Carolyn R. Bertozzi and Stanford bioengineering chair Dr. Jennifer Cochran, reflecting a high-pedigree leadership structure focused on bridging academic innovation with commercial drug discovery.